Myofascial Pain Syndrome in Patients With Breast Cancer-related Lymphedema
NCT ID: NCT06012786
Last Updated: 2025-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
110 participants
OBSERVATIONAL
2023-08-30
2025-02-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions it aims to answer:
* Is there a relationship between the stage of lymphedema and the frequency of accompanying myofascial pain syndrome in the breast cancer patients?
* Does the existence of lymphedema in breast cancer patients affect the distribution and the pain threshold values of trigger points seen in Myofascial Pain Syndrome?
* What is the impact of Myofascial pain syndrome seen in breast cancer associted lymhedema patients on upper extremity function and quality of life?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Elastographic and Ultrasonographic Evaluation of Patients With Breast Cancer Related Lymphedema
NCT06009666
Effectiveness of Stellate Ganglion Block in Breast Cancer Related Lymphedema
NCT04165512
Assessment of Muscle Strength and Volume Changes in Patients With Breast Cancer- Related Lymphedema
NCT03945838
Effect of Different Bandage Interface Pressures on Breast Cancer Related Lymphedema
NCT05660590
Evaluation of the Treatment Response in Breast Cancer Related Lymphedema
NCT04766489
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Upper extremity function is defined by the International Consortium for Measures of Health Outcomes (ICHOM) as one of the most important health measures in breast cancer patients. Long-term upper extremity dysfunction has serious effects on patients' quality of life.
Lymphedema, severe pain, decrease in shoulder joint range of motion, myofascial pain syndrome, myofascial adhesions are the leading causes affecting upper extremity function in patients with breast cancer.
Myofascial pain syndrome (MPS) is commonly seen in patients with musculoskeletal problems and originates from muscle and surrounding tissues. It is characterized by localized or referred pain in a limited area and trigger points in the affected muscles. The incidence of myofascial pain syndrome secondary to breast cancer surgery is unknown. There is not yet a study in the literature that reveals the relationship between the stage of lymphedema and the frequency of accompanying myofascial pain syndrome in the breast cancer patients.
This study is designed as cross sectional- single centered and single blind. It is planned to include 110 breast cancer patients who had undergone the treatments as mastectomy, breast conserving surgery, lymph node dissection, sentinele lymph node biopsy or radiotherapy aged between 18-75 years-old, visiting our oncological rehabilitation outpatient clinic August 2023 through May 2024.
Patients will be divided into 2 groups according to the stage of lymphedema. It is known that pathophysiological changes develop even if there is no visible lymphedema in patients undergoing surgery and/or radiotherapy for breast cancer. There is a lifetime risk of developing lymphedema, so these patients are considered as Stage 0 (latent) . The patients with less than 3 cm difference between the circumference measurements of upper extremities will be included in the 1st group.( Stage 0) (n=55) Patients who have more than 3 cm difference between the circumference measurements of upper extremities and those with Stage 1,2 or 3 lymphedema will be included in the second group (n=55) The frequency of myofascial pain syndrome will be determined by the diagnostic criterias in both groups. The trigger points in trapezius, infraspinatus, serratus anterior, latissimus dorsi and pectoralis major muscles will be examined and the pain-pressure threshold values will be measured with an algometer.
For the evaluation of upper extremity function and quality of life following measurement tools will be utilized in both groups: Hand-grip test with a dynamometer, goniometric measurement of range of motion (ROM) of shoulder joint, VAS numerical scales, LYMQOL and DASH questionnaires.
Data analysis will be performed by using the Statistical Package for the Social Sciences (SPSS, version 20.0, IBM Corp., Armonk, NY, USA).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1 (Patients with Stage 0 lymphedema)
It is known that pathophysiological changes develop even if there is no visible lymphedema in patients undergoing surgery and/or radiotherapy for breast cancer. There is a lifetime risk of developing lymphedema, so these patients are considered as Stage 0 (latent). The patients with less than 3 cm difference between the circumference measurements of upper extremities will be included in the 1st group.( Stage 0) (n=55)
Diagnostic Criteria of Myofascial Pain Syndrome
Major criteria:
1. The patient's complaint of regional pain
2. Referred pain and sensory change in the specific area of the muscle by palpation of the trigger point
3. Presence of palpable taut band
4. Presence of palpable and tender points along the length of the taut band
5. Restriction of ROM in the area of the affected muscle
Minor criteria:
1. Pain/sensory change with pressure palpation of the trigger point
2. Local twitch response with palpation/injection of the trigger point in the taut band
3. Reduction of pain by inactivation (injection or stretching of the muscle) of the trigger point 5 major and at least 1 minor criteria are required for clinical diagnosis
The Physical Examination of Trigger Points and Pain-Pressure Threshold Measurement With an Algometer
Trigger points in trapezius, infraspinatus, latissimus dorsi, pectoralis major, serratus anterior muscles will be detected bilaterally by physical examination. Algometer (Wagner Force Dial FDK 20) will be used for pain pressure threshold measurement of detected trigger points. Then, the distribution of the trigger points, their frequency and threshold values according to the algometer will be compared between the individual affected-insured extremities and between the groups.
Hand Grip Test
The purpose of this test is to test the maximum isometric contraction strength of the hand and forearm muscles. A hand grip dynamometer (Jamar) will be used for the test. While the patient is sitting in the chair, the elbows will be close to the body and at 90 degree flexion, the wrist will be in a neutral position. The patient will be asked to grasp the dynamometer and squeeze it as hard as she can, and the average of 3 measurements made with an interval of 5 minutes. The test will be repeated for both upper extremities separately.
VAS
Shoulder pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
Quick DASH
The quick DASH questionnaire which has proven reliable and valid in breast cancer and lymphedema patients in Turkish population, will be used to evaluate the quality of life related to upper extremity function.
Lymqol-Arm
Lymphedema Quality of Life Scale-Arm Turkish form will be used. The lymphedema-specific quality of life scale was developed specifically for the upper extremity and its reliability and validity were proven in Turkish population.
Range of Motion of Shoulde Joint
Goniometric measurements will be made for both upper extremities, and the average of 3 consecutive measurements will be taken.
Group 2 (Patients with Stage 1,2 or 3 lymphedema)
Patients who have more than 3 cm difference between the circumference measurements of upper extremities and those with Stage 1,2 or 3 lymphedema will be included in the second group (n=55)
Diagnostic Criteria of Myofascial Pain Syndrome
Major criteria:
1. The patient's complaint of regional pain
2. Referred pain and sensory change in the specific area of the muscle by palpation of the trigger point
3. Presence of palpable taut band
4. Presence of palpable and tender points along the length of the taut band
5. Restriction of ROM in the area of the affected muscle
Minor criteria:
1. Pain/sensory change with pressure palpation of the trigger point
2. Local twitch response with palpation/injection of the trigger point in the taut band
3. Reduction of pain by inactivation (injection or stretching of the muscle) of the trigger point 5 major and at least 1 minor criteria are required for clinical diagnosis
The Physical Examination of Trigger Points and Pain-Pressure Threshold Measurement With an Algometer
Trigger points in trapezius, infraspinatus, latissimus dorsi, pectoralis major, serratus anterior muscles will be detected bilaterally by physical examination. Algometer (Wagner Force Dial FDK 20) will be used for pain pressure threshold measurement of detected trigger points. Then, the distribution of the trigger points, their frequency and threshold values according to the algometer will be compared between the individual affected-insured extremities and between the groups.
Hand Grip Test
The purpose of this test is to test the maximum isometric contraction strength of the hand and forearm muscles. A hand grip dynamometer (Jamar) will be used for the test. While the patient is sitting in the chair, the elbows will be close to the body and at 90 degree flexion, the wrist will be in a neutral position. The patient will be asked to grasp the dynamometer and squeeze it as hard as she can, and the average of 3 measurements made with an interval of 5 minutes. The test will be repeated for both upper extremities separately.
VAS
Shoulder pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
Quick DASH
The quick DASH questionnaire which has proven reliable and valid in breast cancer and lymphedema patients in Turkish population, will be used to evaluate the quality of life related to upper extremity function.
Lymqol-Arm
Lymphedema Quality of Life Scale-Arm Turkish form will be used. The lymphedema-specific quality of life scale was developed specifically for the upper extremity and its reliability and validity were proven in Turkish population.
Range of Motion of Shoulde Joint
Goniometric measurements will be made for both upper extremities, and the average of 3 consecutive measurements will be taken.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diagnostic Criteria of Myofascial Pain Syndrome
Major criteria:
1. The patient's complaint of regional pain
2. Referred pain and sensory change in the specific area of the muscle by palpation of the trigger point
3. Presence of palpable taut band
4. Presence of palpable and tender points along the length of the taut band
5. Restriction of ROM in the area of the affected muscle
Minor criteria:
1. Pain/sensory change with pressure palpation of the trigger point
2. Local twitch response with palpation/injection of the trigger point in the taut band
3. Reduction of pain by inactivation (injection or stretching of the muscle) of the trigger point 5 major and at least 1 minor criteria are required for clinical diagnosis
The Physical Examination of Trigger Points and Pain-Pressure Threshold Measurement With an Algometer
Trigger points in trapezius, infraspinatus, latissimus dorsi, pectoralis major, serratus anterior muscles will be detected bilaterally by physical examination. Algometer (Wagner Force Dial FDK 20) will be used for pain pressure threshold measurement of detected trigger points. Then, the distribution of the trigger points, their frequency and threshold values according to the algometer will be compared between the individual affected-insured extremities and between the groups.
Hand Grip Test
The purpose of this test is to test the maximum isometric contraction strength of the hand and forearm muscles. A hand grip dynamometer (Jamar) will be used for the test. While the patient is sitting in the chair, the elbows will be close to the body and at 90 degree flexion, the wrist will be in a neutral position. The patient will be asked to grasp the dynamometer and squeeze it as hard as she can, and the average of 3 measurements made with an interval of 5 minutes. The test will be repeated for both upper extremities separately.
VAS
Shoulder pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
Quick DASH
The quick DASH questionnaire which has proven reliable and valid in breast cancer and lymphedema patients in Turkish population, will be used to evaluate the quality of life related to upper extremity function.
Lymqol-Arm
Lymphedema Quality of Life Scale-Arm Turkish form will be used. The lymphedema-specific quality of life scale was developed specifically for the upper extremity and its reliability and validity were proven in Turkish population.
Range of Motion of Shoulde Joint
Goniometric measurements will be made for both upper extremities, and the average of 3 consecutive measurements will be taken.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients who had signs of active infection as lymphangitis, cellulitis, fungus
* Bilateral breast cancer patients
* Uncontrolled Psychiatric illness
18 Years
75 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yeliz Bahar Özdemir
Role: PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sultan 2. Abdulhamid Han Training and Research Hospital
Istanbul, Kadıköy, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23/338
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.